Breast Elasticity Imaging During Neoadjuvant Chemotherapy
About this study
For this study, the investigators propose investigation of a new imaging technique, Harmonic Motion Imaging (HMI), and the evaluation of its potential role in prediction of breast cancer response to neoadjuvant chemotherapy (NACT). The investigators hypothesize that changes in HMI parameters will predict response to neoadjuvant systemic therapy in early-stage breast cancer.
- Condition
- Breast Cancer
- Tested
- Harmonic motion imaging
- Sponsor
- Columbia University
Who can join
- Age
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
Inclusion 6
- Minimum age: 18 years
- Eligible sex: Female
- Study condition: Breast Cancer
- Women age ≥18
- Deemed eligible to receive neoadjuvant systemic therapy as per the treating physician, with the dose and schedule deemed appropriate by the treating physician.
- Any stage invasive breast cancer provided the primary breast tumor size is ≥ 4 mm
Exclusion 3
- Patient is pregnant or lactating
- Presence of breast implants
- History of laser or radiation therapy to the affected breast
Where
1 site, 1 recruiting
Columbia University Irving Medical Center/NYP
New York, New York, United States
Contact
-
Elisa Konofagou, PhD
212-342-1612 ek2191@columbia.edu
-
Yangpei Liu, MSc
212-342-1612 yl4786@columbia.edu
Potential match only. Final eligibility is determined by the study team.